Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
We’re seeing one of the most challenging moments in HIV prevention history – and the cruelest ironies. On one side, science and advocacy are delivering unprecedented progress via injectable lenacapavir (LEN) for PrEP. On the other, the global systems meant to deliver LEN and other potential innovations are being dismantled.
Blog Post
This week, Zambia joined South Africa in approving injectable lenacapavir for PrEP (LEN), marking a new era of accelerated efforts to scale-up access. At the same time, there’s sharpening analyses of the major shifts in US strategy for foreign aid and global health leadership, with deep implications for the future of funding, multilateralism, and equity.
Blog Post
This round up offers on-the-ground tools for rolling out injectable lenacapavir; updates on AVAC’s court case on foreign assistance; resources on the state of defending rights to health and inclusion for key populations; a look at AVAC’s Advocacy Navigator program; updates on DPP at ICFP; and resources for cure research and the prevention of STIs.
showing 1-10 of 1147
We’re seeing one of the most challenging moments in HIV prevention history – and the cruelest ironies. On one side, science and advocacy are delivering unprecedented progress via injectable lenacapavir (LEN) for PrEP. On the other, the global systems meant to deliver LEN and other potential innovations are being dismantled.
This week, Zambia joined South Africa in approving injectable lenacapavir for PrEP (LEN), marking a new era of accelerated efforts to scale-up access. At the same time, there’s sharpening analyses of the major shifts in US strategy for foreign aid and global health leadership, with deep implications for the future of funding, multilateralism, and equity.
This round up offers on-the-ground tools for rolling out injectable lenacapavir; updates on AVAC’s court case on foreign assistance; resources on the state of defending rights to health and inclusion for key populations; a look at AVAC’s Advocacy Navigator program; updates on DPP at ICFP; and resources for cure research and the prevention of STIs.
By Bridget Jjuuko and Jeanne Baron Last year, Gloria Nawanyaga decided to do something about the devastating numbers of adolescent girls and young women (AGYW) who acquire HIV in her country, Uganda. At approximately 10,000 new cases of HIV among...
Advances over the past ten years toward an HIV cure have moved cure research from a dream to an attainable goal. The field has learned more about the power of the innate immune system through individuals who have controlled their virus, either spontaneously or post-treatment, and these insights have spurred innovation and momentum in cure research.
This week, South Africa became the first African nation to register injectable lenacapavir (LEN) for PrEP. The US released a draft global health “Memorandum of Understanding” (MoU) with serious omissions related to HIV prevention and community engagement; and a leaked document indicates that the European Union may cut future funding to Gavi and the Global Fund. And just as this issue was being published, The Lancet issued a new series, Innovations in Sexual and Reproductive Health.
Enormous changes are underway in HIV prevention and across global health. It’s our work to vigilantly track impacts on research, development and delivery and to call out inequity, greed, misinformation, and misguided assumptions. Here are three questions advocates are asking now along with resources to support this work.
This week major shifts in development finance make headlines as do the real-time consequences of the US cuts to foreign aid and withdrawing from the WHO. AVAC’s new issue of PxWire amplifies issues of access, equity, and accountability with an update on biomedical prevention research and rollout.
The global burden of STIs is staggering with more than one million treatable STIs being acquired daily, and new threats like antibiotic-resistant gonorrhea and rising syphilis cases demanding urgent action. Yet funding, research, and political attention lag far behind the need.
This issue provides a range of maps to help orient the field on critical HIV prevention activities: the status of delivering injectable cabotegravir (CAB for PrEP); funders and countries on track for early introduction of injectable lenacapavir (LEN for PrEP); and where new Phase 3 efficacy trials testing MK-8527 as a monthly pill for PrEP are taking place.
showing 1-10 of 1147
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.